Biomedicine has become a new bright spot for industrial cooperation between Jiangsu and Taiwan

Business Club October 16th As one of the “Jiangsu Taiwan Week” special events, the Sutai Biomedical Health Industry Cooperation Summit held in Taizhou recently attracted more than 200 representatives from the Taiwan business community and related parties. At the same time, the cross-strait (Taizhou) biotechnology industrial park was formally launched in the Taizhou Pharmaceutical Hi-tech Zone. This is the only biotechnology industrial park currently established on the mainland by both sides of the Taiwan Strait. At the same time, 20 Taizhou and Taiwan bio-pharmaceutical cooperation projects were formally signed, with a total investment of 300 million U.S. dollars... With the arrival of the post-Economic Cooperation Framework Agreement (ECFA) era, the bio-pharmaceutical industry is becoming a new cooperation between Jiangsu and Taiwan. Highlights.

Liao Guodong, chairman of the Taiwan Medical Association, believes that at the moment both sides of the strait have invariably listed biopharmaceuticals as one of the emerging strategic industries, indicating that everyone has reached consensus in this area. ECFA has opened five hospitals in the mainland to set up hospitals. Once the hospital is set up, related industries will naturally follow suit. With the reduction of tariffs, Taiwanese companies are looking forward to the cooperation between the two sides in the biomedical field.

In fact, as the country's only national high-tech medicine zone, the China Medical City in Taizhou has attracted nearly 30 Taiwanese biopharmaceutical companies.

“The pharmaceutical market in 2010 is expected to be larger in Asia than in the top five pharmaceutical markets in Europe.” Liu Zhixian, general manager of Taiwan Brilliance International, pointed out that as the Asian market becomes more and more important to the development of new drugs, Prominently, many Taiwanese companies have begun to design clinical trials for new drugs specifically for the mainland market.

"The signing of ECFA not only has great significance for Taiwan, but also has a great impact on the Chinese mainland, especially the biomedical industry in Jiangsu." said Zhang Ying, director of international market development and biotechnology of Jiangsu Wanquan Special Creation Biotech Co., Ltd., Jiangsu biopharmaceutical company. You can take this opportunity to learn that the advanced capital operation mode will grow rapidly, and the mutual establishment of relevant organizations and the mutual recognition of clinical data will shorten the time for new drug submission and simplify the procedures, which will benefit both sides of the pharmaceutical industry.